results of phase i study of mcl-1 inhibition with azd5991 in r/r hematologic malignancies
Published 1 year ago • 151 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
1:35
phase i study of ly3410738: a first-in-class idh1-r132 inhibitor
-
1:18
results of a phase i study of sonrotoclax for the treatment of r/r waldenström’s macroglobulinemia
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
23:23
identifying and treating high-risk patients in 2023
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
44:01
management of the quality in the pre-analytical phase
-
3:38
insights into epim-001 for the treatment of hematological malignancies
-
3:46
overview of a phase i study of ono/gs-4059 in relapsed and refractory mature b-cell malignancies
-
1:24
phase i study of cd123 nk cell engager sar443579 in r/r aml, b-all or hr-mds
-
3:10
results of phase ii trial of olutasidenib in patients with r/r midh1 aml
-
3:52
a phase ii study evaluating the safety and efficacy of olutasidenib in patients with r/r midh1 aml
-
2:19
insights into the phase iia mylox-1 trial: assessing efficacy of gb2064 in myelofibrosis
-
1:40
results from a phase i/ii study of golcadomide in r/r follicular lymphoma
-
2:42
results from a phase i study of cc-98633 in r/r myeloma
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:41
a phase i/ii study of afm13 in combination with cord blood-derived nk cells in patients with r/r hl